Audio Coursesby JellypodLesson 11 of 15
Overview
Explore the evolving challenges of nomenclature in acute respiratory conditions and the nuanced exceptions in ICU protocols. Delve into the preventative shift, the impact of cognitive load, and how precision and leadership shape frontline critical care.
Hamish: Welcome back to The TIME Podcast. Today we’re tackling paediatric lower respiratory tract infections — bronchiolitis, preschool wheeze, and that frustrating overlap where the labels stop helping and clinical judgement takes over.
Jeremy: And what makes this topic interesting in 2025 is that the story isn’t really about a new drug or a single breakthrough. It’s about something much harder — letting go of things we were trained to do, and learning how to sit with uncertainty without filling it with action.
Hamish: At the same time, we’re seeing genuinely new forces entering the space — monoclonal antibodies that change RSV epidemiology, remote monitoring, telehealth, early AI tools. And those don’t always align neatly with the philosophy of restraint.
Jeremy: Exactly. So this episode is really about that tension — what we’ve stopped doing, what we’ve started doing, and where the grey zones still are.
Hamish: Before we talk about treatment, we have to talk about language. Because the way we label these kids quietly dictates what we do next.
Jeremy: Yeah. “Bronchiolitis” has become this catch-all diagnosis that sounds specific but actually isn’t. And when everything is bronchiolitis, everything gets treated the same way.
Hamish: Which historically meant bronchodilators, steroids, antibiotics — regardless of whether the airway physiology made sense.
Jeremy: The newer framework is helpful not because it’s perfect, but because it forces us to slow down. Group A — classic bronchiolitis in young infants. Neutrophil-driven inflammation, mucosal oedema, debris-filled airways.
Hamish: That “snotty lung” picture. And critically, no meaningful bronchospasm.
Jeremy: Which immediately explains why salbutamol doesn’t work — you’re relaxing muscle that isn’t the problem.
Hamish: Group B — viral bronchitis in older infants and preschoolers. Secretions dominate. Still not a smooth-muscle disease.
Jeremy: And Group C — viral-triggered asthma. This is where bronchodilators and steroids actually make sense.
Hamish: The problem is that vague terms like “reactive airways” let us avoid choosing a group — and uncertainty filled with action often causes more harm than uncertainty acknowledged.
Jeremy: And that idea — restraint in the face of uncertainty — becomes a theme for everything else we’re about to talk about.
Hamish: If we zoom in on acute bronchiolitis, this is probably the clearest example of de-implementation driven by evidence rather than fashion.
Jeremy: A good anchor point is the CanBEST trial — the Canadian Bronchiolitis Epinephrine Steroid Trial. Led by Plint and colleagues, across multiple Canadian paediatric EDs, published in NEJM in 2009.
Hamish: The question was straightforward: do epinephrine, dexamethasone, or the combination improve outcomes?
Jeremy: PICO-wise — infants with bronchiolitis, those interventions, placebo comparison, and outcomes like admission rates and clinical improvement.
Hamish: And the answer was essentially no. No meaningful benefit from monotherapy. A modest signal with combination therapy — but not enough to justify routine use.
Jeremy: Which should have been the end of “let’s just try it.”
Hamish: PECARN data reinforced that. Large US multicentre observational analyses showing bronchodilators and steroids don’t reduce length of stay, oxygen use, or admissions.
Jeremy: Different methodology, same conclusion. And importantly, absence of benefit matters when the harms — agitation, tachycardia, false reassurance — aren’t theoretical.
Hamish: Hypertonic saline is a nice example of how hard it is to let go.
Jeremy: Early Cochrane reviews suggested shorter hospital stays — about a day — based on small trials.
Hamish: Then larger pragmatic studies arrived. One often cited is the Teunissen et al. multicentre European trial from the mid-2020s.
Jeremy: Hospitalised infants, 3% saline versus normal saline, looking at length of stay.
Hamish: And what emerged was heterogeneity. Some sites saw small effects, others none. No consistent, clinically meaningful benefit.
Jeremy: Which is why guidelines softened — not because it’s dangerous, but because it doesn’t reliably help.
Hamish: This pattern keeps repeating: physiology makes sense, clinicians feel better, outcomes don’t move.
Jeremy: Oxygen is where many of us still feel uncomfortable.
Hamish: The BIDS trial — Cunningham et al., UK, Lancet 2015 — forced the issue.
Jeremy: Lower oxygen targets — 90% instead of 94%. Non-inferior outcomes, earlier discharge.
Hamish: Which exposed how much oxygen therapy was about clinician anxiety rather than infant physiology.
Jeremy: Hydration followed the same arc. The CRIB trial — Oakley et al., ANZ, Lancet 2013 — compared NG and IV fluids.
Hamish: Equivalent safety, higher success rates with NG, fewer complications.
Jeremy: And at scale, at night, with junior staff — that matters.
Hamish: This is where bronchiolitis stops being a ward problem and becomes something else entirely.
Jeremy: And that distinction really matters, because ICU bronchiolitis isn’t just “worse bronchiolitis” — it’s often a different physiological state altogether.
Hamish: Exactly. Once an infant is on positive pressure support, the balance shifts. You’re no longer just dealing with mucosal oedema and secretions — you’re dealing with dynamic hyperinflation, altered lung compliance, and a significant inflammatory burden.
Jeremy: Which is why the DAB trial is interesting — but also dangerous if misunderstood.
Hamish: Just to recap the evidence briefly: multicentre Australasian PICU RCT, infants with severe bronchiolitis requiring positive pressure support. Combined dexamethasone and nebulised adrenaline reduced duration of support — roughly forty hours down to the mid-twenties.
Jeremy: And critically, the signal was strongest in infants with radiological hyperinflation. That’s not incidental — it suggests that in this subgroup, airway inflammation and air trapping are actually contributing meaningfully to ongoing respiratory failure.
Hamish: But here’s the trap. This is not evidence that “steroids work in bronchiolitis again.” It’s evidence that in a very narrow physiological state, anti-inflammatory and adrenergic effects may shorten support duration.
Jeremy: And the danger is how quickly that nuance gets lost. ICU evidence has a habit of leaking downstream — into HDU, then wards, then ED — without the physiological guardrails that made it safe in the first place.
Hamish: Which is why the guidelines are deliberately conditional here. This is not an invitation to re-medicalise bronchiolitis. It’s an exception, not a reversal.
Jeremy: One of the things that worries me is how exceptions quietly become norms.
Hamish: Yes — especially in environments under pressure. Once people know there’s something you can do in ICU, that knowledge doesn’t stay contained
Jeremy: And suddenly you’re seeing steroids trialled in borderline cases, or adrenaline given “just to see”, not because the physiology fits — but because uncertainty feels uncomfortable.
Hamish: That’s a systems failure, not an individual one. We train clinicians to act, then we give them ambiguous evidence and expect restraint without support.
Hamish: Preschool wheeze is almost the mirror image of bronchiolitis.
Jeremy: Yeah — instead of over-treating a self-limiting disease, we’re trying not to under-recognise an evolving one.
Hamish: EVW versus MTW helps conceptually, but clinically it’s slippery. Kids don’t declare themselves neatly, and phenotypes drift.
Jeremy: Which is why time — and response to therapy — becomes the diagnostic tool. An 8–12-week ICS trial isn’t about committing to a diagnosis; it’s about observing trajectory.
Hamish: And that’s where montelukast becomes problematic. Historically it’s been attractive because it feels low-risk and easy.
Jeremy: But the observational data from 2024–2025 change that calculus. Large population cohorts, montelukast versus ICS, looking at neuropsychiatric outcomes.
Hamish: Around a 30% increase in serious behavioural events. Not subtle. And while it’s observational, the signal is consistent across datasets.
Jeremy: Which means prescribing montelukast now carries a different ethical weight. You’re not choosing a benign alternative — you’re choosing a trade-off that families need to understand.
Hamish: Let’s slow down on prevention, because nirsevimab isn’t just another therapeutic — it fundamentally changes the shape of the problem we’ve been talking about.
Jeremy: Exactly. Most of paediatric respiratory medicine has been reactive. RSV arrives, wards fill, ICUs stretch, and we argue about thresholds and flow. Nirsevimab is different because it intervenes before any of that starts.
Hamish: And the scale of effect matters here. The real-world data from the 2024–2025 RSV season — particularly from US registry data and the Catalonian rollout — showed an adjusted hazard ratio for RSV hospitalisation of about 0.23.
Jeremy: That’s a seventy-plus percent reduction in instantaneous risk. In paediatrics, we almost never see effects of that magnitude outside vaccination programmes.
Hamish: But what’s important is where that benefit shows up. It’s not just fewer bronchiolitis admissions — it’s fewer infants progressing to hypoxic respiratory failure, fewer ICU referrals, fewer winter surge crises.
Jeremy: Which means this isn’t just a patient-level intervention. It’s a capacity intervention. It changes staffing models, bed availability, retrieval demand, even how EDs experience winter.
Hamish: But here’s where it gets interesting — and a bit uncomfortable. When you reduce RSV burden this dramatically, you don’t just change disease incidence. You change clinician behaviour.
Jeremy: Yes. RSV becomes less visible. Less expected. And that has consequences.
Hamish: We’ve seen this before with other successful public health interventions. When something becomes rare, vigilance drops. Pattern recognition weakens.
Jeremy: Which means the next sick infant with respiratory failure may not fit the mental model clinicians are primed for. The risk isn’t that RSV disappears — it’s that we stop expecting it to be severe.
Hamish: And that matters in borderline cases. The infant who doesn’t quite look like classic bronchiolitis. The child whose trajectory feels “off” but doesn’t trigger alarms.
Jeremy: There’s also an immunological humility we need to maintain here. Nirsevimab provides passive immunity — it doesn’t stimulate endogenous immune memory in the way natural infection or vaccination does.
Hamish: And right now, our data are excellent for one season. Beyond that, we’re extrapolating.
Jeremy: We don’t yet know whether widespread passive immunisation alters the timing or phenotype of later RSV infections. We don’t know if we’re simply deferring disease, attenuating it, or reshaping it entirely
Hamish: And to be clear — there’s no signal of harm so far. But absence of evidence isn’t evidence of absence, particularly for long-term population effects.
Jeremy: Which is why it’s important we don’t oversell certainty. This is powerful prevention, but it’s not immunological closure.
Hamish: There’s also the unresolved question of combination strategies. Maternal RSV vaccination plus infant nirsevimab.
Hamish: Right now, we simply don’t have outcome data on that combination. We assume additive benefit, but that’s an assumption — not evidence.
Hamish: And that matters for policy. Do we target high-risk infants with both? Do we stratify by gestational age, comorbidity, or seasonality?
Jeremy: These are not academic questions. They drive procurement, consent discussions, and equity decisions.
Hamish: There’s also an equity lens here that’s easy to miss.
Jeremy: Absolutely. RSV burden is not evenly distributed. Indigenous communities, rural populations, socioeconomically disadvantaged families bear a disproportionate share of severe disease.
Hamish: Which means that how prevention is rolled out matters as much as whether it works.
Jeremy: If access is patchy, if uptake favours well-resourced systems, we risk widening gaps while congratulating ourselves on population-level success.
Hamish: And perhaps the most important point — prevention doesn’t eliminate uncertainty. It just moves it.
Jeremy: Exactly. You still need to recognise the sick child. You still need to manage the grey zones. You still need escalation pathways that work.
Hamish: In some ways, prevention makes judgement harder, because the expected patterns change.
Hamish: And I think this is the moment where prevention quietly reshapes everything else we do.
Jeremy: Because when RSV admissions fall, pressure doesn’t vanish — it shifts to the margins. The borderline infants. The ones with sats in the low nineties, feeding a bit less, work of breathing you’re not thrilled about… but not clearly sick enough to admit.
Hamish: And when you’re living at the margins, systems reach for surveillance instead of beds.
Jeremy: Exactly. Monitoring feels like the compromise: don’t admit “just in case” — watch instead.
Hamish: But we have to be honest: pulse oximetry doesn’t just measure oxygen. It changes decisions.
Jeremy: If we’re talking remote monitoring, we need to start with the trial that proves numbers steer behaviour: Schuh et al., JAMA 2014, conducted in a tertiary paediatric ED in Toronto — a randomised, double-blind trial where displayed saturations were either true or artificially increased by 3%.
Hamish: PICO:Population: otherwise healthy infants (4 weeks–12 months) with mild–moderate bronchiolitisIntervention: oximetry display altered upward by ~3%Comparison: true oximetry display. Outcome: hospitalisation (within 72 hours), plus ED course measures
Jeremy: Meaning: tiny changes in a number change admissions. Not because the baby changed — because the clinician changed.
Hamish: So when you export oximetry into the home, you’re not exporting “data.” You’re exporting a behavioural trigger.
Jeremy: Now, the argument for home monitoring is: “kids desaturate at home; we’ll catch it.” That’s why Principi et al., JAMA Pediatrics 2016 matters — cohort study, again from Toronto, following infants discharged from ED with bronchiolitis with home oximetry.
Hamish: PICO:Population: infants discharged from ED with bronchiolitis (deemed safe for discharge)Exposure: desaturations <90% for ≥1 minute during home oximetryComparison: infants without such desaturationsOutcome: unscheduled medical visits within 72 hours and delayed hospitalisation
Hamish: They found desaturations were very common — but they didn’t predict who re-presented.
Jeremy: Which is the key warning: if the signal is common and poorly predictive, you create noise. And noise drives anxiety, escalation, and admissions — exactly what “remote monitoring to avoid admission” was meant to prevent.
Hamish: Now, to be fair, there’s a different intervention that sometimes gets mixed into the same conversation: not “home oximetry,” but “home care with oxygen plus structured follow-up.”
Jeremy: A good anchor is Freeman, Deakyne, Bajaj — Academic Emergency Medicine 2017: prospective observational study of ED-initiated home oxygen for hypoxemic bronchiolitis from a tertiary paediatric ED in Colorado, across multiple winter seasons.
Hamish: PICO:Population: hypoxemic bronchiolitis patients (3–18 months) evaluated in EDIntervention: discharge with home oxygen + structured follow-up contactsComparison: observational design (no randomised inpatient comparator in this paper)Outcome: adverse events, follow-up success, duration of oxygen, failure rates, caregiver experience
Jeremy: The lesson isn’t “home oxygen fixes bronchiolitis.” The lesson is: when home management is safe, it’s usually because it’s a service model — selection criteria, follow-up, escalation ownership — not because you handed someone a device.
Hamish: This is where remote monitoring can become deceptively reassuring. Visibility feels like control.
Jeremy: But visibility isn’t ownership. Seeing a saturation trace doesn’t tell you who’s responsible for acting, and paediatric deterioration is often nonlinear. Infants compensate — until they don’t.
Hamish: And reassurance isn’t benign. It changes behaviour. Parents wait longer. Clinicians deprioritise. The system quietly reclassifies the child as “safe.” Then deterioration declares itself late — fatigue, feeding collapse, rising CO₂, and suddenly you’ve lost margin.
Jeremy: There’s another uncomfortable truth: our baseline monitoring culture is already distorted.
Hamish: The multicentre study “Prevalence of Continuous Pulse Oximetry Monitoring in Hospitalized Children With Bronchiolitis Not Requiring Supplemental Oxygen,” JAMA 2020 showed continuous monitoring was common and variable even when kids weren’t on oxygen — classic medical overuse.
Jeremy: PICO:Population: hospitalised children with bronchiolitis not requiring supplemental oxygenExposure/Intervention: continuous pulse oximetry useComparison: between hospitals/units and implied “not indicated” baselineOutcome: prevalence/variation (and the known downstream links to prolonged LOS in prior literature)
Hamish: So if we struggle to de-implement low-value monitoring inside hospitals, why do we assume we’ll implement higher-value monitoring outside them — safely — without strict governance?[
Jeremy: And cognitive load matters: every alert competes with ten others. Clinicians adapt not because they don’t care, but because sustained hypervigilance is impossible.
Hamish: I still think, designed well, remote monitoring can reduce unnecessary admissions.
Jeremy: I think it often delays them — and pushes the admission decision later into the illness trajectory.
Hamish: But that assumes poor escalation pathways.
Jeremy: No — it assumes normal human behaviour under uncertainty. Families don’t want to overreact. Clinicians don’t want to over-medicalise. Everyone waits for clarity.
Hamish: I don’t think that outcome is inevitable.
Hamish: I think it’s common enough that leaders need to plan for it rather than assume best-case behaviour.
Jeremy: This is where governance either exists or it doesn’t: when an alert fires at 2am, who owns that moment?
Hamish: Who reviews the data? Who has authority to escalate? Who carries liability if escalation doesn’t happen?[
Jeremy: If those answers aren’t explicit, governance is being simulated, not enacted.
Hamish: And risk drifts downward — onto junior clinicians triaging alerts without authority, and onto families interpreting numbers they didn’t ask for.
Hamish: So Monday morning. You’re a director. Winter’s coming. RSV admissions are down. Staffing is tight.
Jeremy: You’re offered a remote monitoring pathway for infants with sats between 90 and 94%. It promises fewer admissions and better flow.
Hamish: But it also shifts risk into homes, inboxes, and escalation grey zones.
Jeremy: There’s no clean answer.
Hamish: But there is a wrong one — pretending it’s risk-free.
Hamish: Everything we’ve talked about today — de-implementation, prevention, monitoring — comes back to the same question.
Jeremy: Not “can we do this?” but “who owns the consequences when it doesn’t work?”
Hamish: Modern paediatric respiratory care isn’t about doing more or less.
Jeremy: It’s about doing deliberately — and owning the trade-offs.
Hamish: If this made you uncomfortable, that’s appropriate.
Jeremy: Because the hardest part of this work isn’t knowledge. It’s restraint, accountability, and leadership in the grey zone.
Hamish: Thanks for listening to The TIME Podcast. Supplementary material and access to the supporting datasets and references are available in the members section at Clintix.com.
Hamish: And if you’re listening at the conference — take this into your own service: what are you still doing that doesn’t help, and what are you rolling out that shifts risk without naming it?
Hamish: We’ll see you next time — and again, for the reference list and supporting material, head to the members section at Clintix.com.
